Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000

International Journal of Infectious Diseases

Volumn 8, Issue 6, 2004, Pages 362-373

  Koeth, Laura M ^a   Jacobs, Michael R ^b   Good, Caryn E ^b   Bajaksouzian, Saralee ^b   Windau, Anne ^b   Jakielaszek, Charles ^c   Saunders, Kay A ^c  

^a Laboratory Specialists Inc   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Amoxicillin Clavulanic Acid; Haemophilus influenzae; In vitro susceptibility; Moraxella catarrhalis; Streptococcus pneumoniae; Surveillance

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAMASE; CEFACLOR; CEFIXIME; CEFPROZIL; CEFTRIAXONE; CEFUROXIME AXETIL; CLARITHROMYCIN; CLAVULANIC ACID; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; AUSTRALIA; BACTERIAL STRAIN; BACTERIAL VIRULENCE; DRUG ACTIVITY; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; DRUG SENSITIVITY; EUROPE; HAEMOPHILUS INFLUENZAE; HONG KONG; HUMAN; IN VITRO SELECTION; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NORTH AMERICA; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIA;

ADMINISTRATION, ORAL; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; AUSTRALIA; DRUG RESISTANCE, BACTERIAL; EUROPE; HAEMOPHILUS INFLUENZAE; HONG KONG; HUMANS; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; NORTH AMERICA; POPULATION SURVEILLANCE; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 5644279011     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2004.02.005     Document Type: Article

References (35)

1. J.L. Murray A.D. Lopez The global burden of disease 1996 Harvard University Press Cambridge, MA 5
2. E. Arias, R. Anderson, H. Kung, S. Murphy, and K. Kochanek Centers for Disease Control and Prevention U.S. Department of Health and Human Services. Deaths: final data for 2001 Natl Vital Stat Rep 52 2003 8
3. J.G. Bartlett, and L.M. Mundy Community-acquired pneumonia New Engl J Med 333 1995 1618 1624
4. L. Ostergaard, and P.L. Andersen Etiology of community-acquired pneumonia. Evaluation by transtracheal aspiration, blood culture, or serology Chest 104 1993 1400 1407
5. M. Ruiz, S. Ewig, A. Torres, F. Arancibia, F. Marco, J. Mensa, M. Sanchez, and J.A. Martinez Severe community-acquired pneumonia: risk factors and follow-up epidemiology Am J Respir Crit Care Med 160 1999 923 929
6. Sinus and Allergy Health Partnership Antimicrobial treatment guidelines for acute bacterial rhinosinusitis Otolaryngol-Head Neck Surg Suppl 123 2000 S1 S32
7. M.J. Fine, M.A. Smith, and C.A. Carson Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis JAMA 275 1996 134 141
8. S. Sethi Infectious exacerbations of chronic bronchitis: diagnosis and management J Antimicrob Chemother 43 1999 S97 S105
9. P. Moine, J.B. Vercken, S. Chevret, C. Chastang, and P. Gajdos Severe community-acquired pneumonia: etiology, epidemiology, and prognosis factors Chest 105 1994 1487 1495
10. Benenson AS. Control of communicable diseases manual. 16th edition. Washington DC: American Public Health Association; 1995. pp. 256-8, 368.
11. L.M. Deshpande, and R.N. Jones Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community acquired respiratory tract infections in the United States (1999) Diagn Microbiol Infect Dis 37 2000 139 142
12. R.N. Jones, and M.A. Pfaller In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: Data from the SENTRY antimicrobial surveillance program Clin Infect Dis 31 2000 S16 S23
13. C.M. Kaye, A. Allen, S. Perry, M. McDonagh, M. Davy, K. Storm, N. Bird, and O. Dewit The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate Clin Ther 23 2001 578 584
14. M.R. Jacobs How can we predict bacterial eradication? Int J Infect Dis 7 2003 S13 S19
15. D.J. Hoban, G.V. Doern, A.C. Fluit, M. Roussel-Delvallez, and R. Jones Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999 Clin Infect Dis 32 2001 S81 S93
16. W.A. Craig, and D. Andes Pharmacokinetics and pharmacodynamics of antibiotics in otitis media Pediatr Infect Dis J 15 1996 255 259
17. T.M. File, M.R. Jacobs, M.D. Poole, and B. Wynne Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxicillin/ clavulanate Int J Antimicrob Agents 20 2002 235
18. Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of clinical microbiology. 7th edition. Washington, DC: ASM Press; 1999. pp. 134-5, 245-9, 466-8.
19. National Committee for Clinical Laboratory Standards Approved standard M7-A4. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically 4th edition. 1997 NCCLS Wayne, PA
20. National Committee for Clinical Laboratory Standards M100-S12 Performance standards for antimicrobial susceptibility testing-Tenth Informational Supplement 2002 NCCLS Wayne, PA
21. W.A. Craig Pharmacokinetic/pharacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1998 1 10
22. C.H. Nightingale Pharmacokinetics and pharmacodynamics of newer macrolides Pediatr Infect Dis J 16 1995 438 443
23. Christianson J, Andes D, Craig W. Characterization of the pharmacodynamics of doxycycline against Streptococcus pneumoniae in a murine thigh-infection model. ICAAC 2001. Proceedings of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, 2001; Washington DC: American Society of Microbiology, p 27.
24. M.R. Jacobs, S. Bajaksouzian, A. Zilles, G. Lin, G.A. Pankuch, and P.C. Appelbaum Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US surveillance study Antimicrob Agents Chemother 43 1999 1901 1908
25. D.A. Preston, M.R. Turnak, M.R. Jacobs, P.C. Appelbaum, G.G. Zhanel, and D.E. Low Assumed versus approved breakpoints Antimicrob Agents Chemother 44 2000 3243 3245
26. M.R. Jacobs Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters Clin Microbiol Infect 11 2001 589 596
27. P. Petitpretz, C. Chidiac, F. Soriano, J. Garau, K. Stevenson, and E. Rouffiac The efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate 2000/125 mg, twice daily, versus oral amoxicillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community acquired pneumoniae in adults Int J Antimicrob Agents 20 2000 119 129
28. E.O. Mason Jr., L.B. Lamberth, N.L. Kershaw, B.L. Prosser, A. Zoe, and P.G. Ambrose Streptococcus pneumoniae in the USA: in vitro susceptibility and pharmacodynamic analysis J Antimicrob Chemother 45 2000 623 631
29. C. Thornsberry, and D.F. Sahm Antimicrobial resistance in respiratory tract pathogens: results of an international surveillance study Chemotherapy 46 2000 S15 S23
30. R.N. Jones The impact of antimicrobial resistance: Changing epidemiology of community-acquired respiratory-tract infections Am J Health Syst Pharm 56 1999 S4 S11
31. M.R. Jacobs, D. Felmingham, P.C. Appelbaum, and R.N. Gruneberg The Alexander Project. 1998-2000: susceptibility of pathogens insolated from community-acquired respiratory tract infection to commonly used antimicrobial agents J Antimicrob Chemother 52 2003 229 246
32. M.K. York, L. Gibbs, F. Perdreau-Remington, and G.F. Brooks Characterization of antimicrobial resistance in Streptococcus pyogenes isolates from the San Francisco Bay area of Northern California J Clin Microbiol 37 1999 1727 1731
33. W. Cullman Comparative evaluation of orally active antibiotics against community-acquired pathogens: results of eight European countries Chemotherapy 42 1996 11 20
34. E.L. Kaplan, D.R. Johnson, M.C. Del Rosario, and D.L. Horn Susceptibility of group A beta-hemolytic streptococci to thirteen antibiotics: examination of 301 strains isolated in the United States between 1994 and 1997 Pediatr Infect Dis J 18 1999 1069 1072
35. P.E. Varaldo, E.A. Debbia, G. Nicoletti, D. Pavesio, S. Ripa, and G.C. Schito Nationwide survey in Italy of treatment of Streptococcus pyogenes pharyngitis in children: influence of macrolide resistance on clinical and microbiological outcomes Clin Infect Dis 29 1999 869 873